Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning
The Bayesian adaptive dosing strategy significantly improves the accuracy of achieving the target busulfan AUC in patients undergoing HCT. This approach not only reduces marked deviations from target exposure, but also reduces the incidence of busulfan-related toxicity, thereby maintaining a favourable toxicity/efficacy ratio.
Authors
- Benjamin Bouchacourt (ORCID: https://orcid.org/0000-0003-3908-2595)
- Laure Carriat
- Dorian Protzenko (ORCID: https://orcid.org/0009-0002-9065-2899)
- Raynier Devillier
- Joseph Ciccolini (ORCID: https://orcid.org/0000-0003-1733-3410)
- Paul Maroselli
- C. Boéri
Institutions
- Inserm (FR)
- Aix-Marseille Université (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1111/bcp.16343
- Citations
- 3
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.36